Astronics Corporation Reports 2021 Third Quarter Financial Results
Astronics Corporation (Nasdaq: ATRO) reported a 5% increase in quarterly sales to $111.8 million compared to last year. Despite a net loss of $7.2 million, the company noted sequential improvement in losses through 2021. Adjusted EBITDA rose to $2.8 million. Bookings surged by 88% year-over-year, totaling $153.5 million, achieving a book-to-bill ratio of 1.37. Although supply chain issues impacted sales by approximately $10 million, the company anticipates stronger demand going into Q4 2021.
- Sales increased 5% YoY to $111.8 million.
- Bookings surged 88% YoY to $153.5 million.
- Achieved book-to-bill ratio of 1.37.
- Adjusted EBITDA improved to $2.8 million.
- Net loss of $7.2 million, widening from last year's loss.
- Sales impacted by $8-$10 million due to supply chain issues.
- Test Systems segment sales down $7.9 million YoY.
-
Sales for the quarter were
, up$111.8 million 5% over prior-year period -
Net loss of
continues sequential improvement through 2021$7.2 million -
Adjusted EBITDA* was
; measurably improved over prior-year period loss and trailing second quarter$2.8 million -
Bookings up
88% over prior-year period and up22% over trailing second quarter to ; Achieved book-to-bill ratio of 1.37$153.5 million - Aerospace segment book-to-bill was 1.49 for the quarter
-
Backlog increased
13% sequentially to$354.4 million
*Adjusted EBITDA is a Non-GAAP Performance Measure. Please see the attached table for a reconciliation of adjusted EBITDA to GAAP net income.
Third Quarter Results
|
Three Months Ended |
|
Nine Months Ended |
|||||||||||||||||
($ in thousands) |
2021 |
|
2020 |
% Change |
|
2021 |
|
2020 |
% Change |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Sales |
$ |
111,841 |
|
|
$ |
106,506 |
|
5.0 |
% |
|
$ |
328,856 |
|
|
$ |
387,784 |
|
(15.2 |
)% |
|
Loss from Operations |
$ |
(4,498 |
) |
|
$ |
(8,997 |
) |
50.0 |
% |
|
$ |
(19,930 |
) |
|
$ |
(95,232 |
) |
79.1 |
% |
|
Operating Margin % |
(4.0 |
)% |
|
(8.4 |
)% |
|
|
(6.1 |
)% |
|
(24.6 |
)% |
|
|||||||
Net Loss |
$ |
(7,174 |
) |
|
$ |
(5,254 |
) |
(36.5 |
)% |
|
$ |
(27,182 |
) |
|
$ |
(95,796 |
) |
71.6 |
% |
|
Net Loss % |
(6.4 |
)% |
|
(4.9 |
)% |
|
|
(8.3 |
)% |
|
(24.7 |
)% |
|
|||||||
*Adjusted EBITDA |
$ |
2,836 |
|
|
$ |
(55 |
) |
5,256.4 |
% |
|
$ |
2,703 |
|
|
$ |
25,865 |
|
(89.5 |
)% |
|
*Adjusted EBITDA Margin % |
2.5 |
% |
|
(0.1 |
)% |
|
|
0.8 |
% |
|
6.7 |
% |
|
|||||||
*Adjusted EBITDA is a Non-GAAP Performance Measure. Please see the attached table for a reconciliation of adjusted EBITDA to GAAP net income. |
Third Quarter 2021 Results (compared with the prior-year period, unless noted otherwise)
Consolidated sales were up
The Company was awarded a grant of up to
Consolidated operating loss improved measurably over the prior-year period as higher volume reflecting improvements in the commercial aerospace and the benefit of the AMJP helped to offset the impacts of supply chain constraints.
Consolidated net loss was
Consolidated adjusted EBITDA was
Sequentially, compared with the second quarter of 2021, while revenue remained consistent, net loss improved to
Bookings were
Aerospace Segment Review (refer to sales by market and segment data in accompanying tables)
Aerospace Third Quarter 2021 Results (compared with the prior-year period, unless noted otherwise)
Aerospace segment sales increased
Military Aircraft sales decreased
Other revenue increased
Aerospace segment operating profit was
Sequentially, compared with the second quarter of 2021, Aerospace revenue grew
Aerospace bookings in the third quarter of 2021 were
Test Systems Segment Review (refer to sales by market and segment data in accompanying tables)
Test Systems Third Quarter 2021 Results (compared with the prior-year period, unless noted otherwise)
Test Systems segment sales were
Test Systems operating loss was
Bookings for the Test Systems segment in the quarter were
Liquidity and Financing
At
Cash used by operations totaled
In September, the
The Company expects additional cash inflows over the next several quarters related to an earn out from the 2019 sale of its semiconductor test business, an approximate
2021 Outlook
Based on current estimates, the Company expects the AMJP to contribute approximately
At the end of the third quarter, the Company had backlog of
Planned capital expenditures for 2021 have been reduced to approximately
Third Quarter 2021 Webcast and Conference Call
The Company will host a teleconference today at
The
About
Safe Harbor Statement
This news release contains forward-looking statements as defined by the Securities Exchange Act of 1934. One can identify these forward-looking statements by the use of the words “expect,” “anticipate,” “plan,” “may,” “will,” “estimate” or other similar expressions and include all statements with regard to the impact of COVID-19 on the Company and its future, reaching any revenue or Adjusted EBITDA margin expectations, being in compliance with credit agreement covenants, the recovery of the commercial aerospace and test systems markets, the opportunities to leverage capabilities in other markets and the outcome of demand streams or expectations of demand by customers and markets. Because such statements apply to future events, they are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the statements. Important factors that could cause actual results to differ materially from what may be stated here include the impact of the global outbreak of COVID-19 and governmental and other actions taken in response, trend in growth with passenger power and connectivity on airplanes, the state of the aerospace and defense industries, the market acceptance of newly developed products, internal production capabilities, the timing of orders received, the status of customer certification processes and delivery schedules, the demand for and market acceptance of new or existing aircraft which contain the Company’s products, the need for new and advanced test and simulation equipment, customer preferences and relationships, and other factors which are described in filings by
FINANCIAL TABLES FOLLOW
|
||||||||||||||||
CONSOLIDATED STATEMENT OF OPERATIONS DATA |
||||||||||||||||
(Unaudited, $ in thousands except per share data) |
||||||||||||||||
|
|
|
|
|||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
|||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Sales |
$ |
111,841 |
|
|
$ |
106,506 |
|
|
$ |
328,856 |
|
|
$ |
387,784 |
|
|
Cost of products sold |
94,610 |
|
|
91,333 |
|
|
281,957 |
|
|
310,059 |
|
|||||
Gross profit |
17,231 |
|
|
15,173 |
|
|
46,899 |
|
|
77,725 |
|
|||||
Gross margin |
15.4 |
% |
|
14.2 |
% |
|
14.3 |
% |
|
20.0 |
% |
|||||
|
|
|
|
|
|
|
|
|||||||||
Selling, general and administrative2 |
21,729 |
|
|
24,170 |
|
|
66,829 |
|
|
85,941 |
|
|||||
SG&A % of sales |
19.4 |
% |
|
22.7 |
% |
|
20.3 |
% |
|
22.2 |
% |
|||||
Impairment loss1 |
— |
|
|
— |
|
|
— |
|
|
87,016 |
|
|||||
Loss from operations |
(4,498 |
) |
|
(8,997 |
) |
|
(19,930 |
) |
|
(95,232 |
) |
|||||
Operating margin |
(4.0 |
)% |
|
(8.4 |
)% |
|
(6.1 |
)% |
|
(24.6 |
)% |
|||||
|
|
|
|
|
|
|
|
|||||||||
Other expense, net of other income |
546 |
|
|
369 |
|
|
1,627 |
|
|
4,546 |
|
|||||
Interest expense, net |
1,795 |
|
|
1,775 |
|
|
5,252 |
|
|
5,091 |
|
|||||
Loss before tax |
(6,839 |
) |
|
(11,141 |
) |
|
(26,809 |
) |
|
(104,869 |
) |
|||||
Income tax expense (benefit) |
335 |
|
|
(5,887 |
) |
|
373 |
|
|
(9,073 |
) |
|||||
Net loss |
$ |
(7,174 |
) |
|
$ |
(5,254 |
) |
|
$ |
(27,182 |
) |
|
$ |
(95,796 |
) |
|
Net loss % of sales |
(6.4 |
)% |
|
(4.9 |
)% |
|
(8.3 |
)% |
|
(24.7 |
)% |
|||||
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|||||||||
*Basic loss per share: |
$ |
(0.23 |
) |
|
$ |
(0.17 |
) |
|
$ |
(0.88 |
) |
|
$ |
(3.11 |
) |
|
*Diluted loss per share: |
$ |
(0.23 |
) |
|
$ |
(0.17 |
) |
|
$ |
(0.88 |
) |
|
$ |
(3.11 |
) |
|
|
|
|
|
|
|
|
|
|||||||||
*Weighted average diluted shares outstanding (in thousands) |
30,954 |
|
|
30,770 |
|
|
30,927 |
|
|
30,780 |
|
|||||
|
|
|
|
|
|
|
|
|||||||||
Capital expenditures |
$ |
1,073 |
|
|
$ |
1,670 |
|
|
$ |
4,639 |
|
|
$ |
5,575 |
|
|
Depreciation and amortization |
$ |
7,071 |
|
|
$ |
8,043 |
|
|
$ |
21,950 |
|
|
$ |
24,095 |
|
|
1 Impairment loss primarily represents the goodwill impairment charges incurred in the Aerospace segment. Full impairment charges totaling |
|
2 Includes fair value adjustment of contingent consideration liabilities, which was a |
|
||||||||||||||
SEGMENT DATA |
||||||||||||||
(Unaudited, $ in thousands) |
||||||||||||||
|
|
|
||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
|||||||||||
|
|
|
|
|
|
|||||||||
Sales |
|
|
|
|
|
|||||||||
Aerospace |
$ |
95,775 |
|
$ |
82,548 |
|
|
$ |
266,425 |
|
$ |
326,282 |
|
|
Less inter-segment |
(9 |
) |
— |
|
|
(23 |
) |
(91 |
) |
|||||
|
95,766 |
|
82,548 |
|
|
266,402 |
|
326,191 |
|
|||||
|
|
|
|
|
|
|||||||||
Test Systems |
16,128 |
|
24,406 |
|
|
62,811 |
|
62,391 |
|
|||||
Less inter-segment |
(53 |
) |
(448 |
) |
|
(357 |
) |
(798 |
) |
|||||
Total Test Systems |
16,075 |
|
23,958 |
|
|
62,454 |
|
61,593 |
|
|||||
Total consolidated sales |
111,841 |
|
106,506 |
|
|
328,856 |
|
387,784 |
|
|||||
|
|
|
|
|
|
|||||||||
Segment operating profit (loss) and margins |
|
|
|
|
|
|||||||||
Aerospace |
1,917 |
|
(6,332 |
) |
|
(6,352 |
) |
(86,567 |
) |
|||||
|
2.0 |
% |
(7.7 |
)% |
|
(2.4 |
)% |
(26.5 |
)% |
|||||
Test Systems |
(2,201 |
) |
936 |
|
|
(1,958 |
) |
4,270 |
|
|||||
|
(13.7 |
)% |
3.9 |
% |
|
(3.1 |
)% |
6.9 |
% |
|||||
Total segment operating profit (loss) |
(284 |
) |
(5,396 |
) |
|
(8,310 |
) |
(82,297 |
) |
|||||
|
|
|
|
|
|
|||||||||
Interest expense |
1,795 |
|
1,775 |
|
|
5,252 |
|
5,091 |
|
|||||
Corporate expenses and other |
4,760 |
|
3,970 |
|
|
13,247 |
|
17,481 |
|
|||||
Loss before taxes |
$ |
(6,839 |
) |
$ |
(11,141 |
) |
|
$ |
(26,809 |
) |
$ |
(104,869 |
) |
|
Reconciliation to Non-GAAP Performance Measures
In addition to reporting net income, a
|
||||||||||||||||
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA |
||||||||||||||||
(Unaudited, $ in thousands) |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Consolidated |
||||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
|||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net loss |
$ |
(7,174 |
) |
|
$ |
(5,254 |
) |
|
$ |
(27,182 |
) |
|
$ |
(95,796 |
) |
|
Add back (deduct): |
|
|
|
|
|
|
|
|||||||||
Interest expense |
1,795 |
|
|
1,775 |
|
|
5,252 |
|
|
5,091 |
|
|||||
Income tax expense (benefit) |
335 |
|
|
(5,887 |
) |
|
373 |
|
|
(9,073 |
) |
|||||
Depreciation and amortization expense |
7,071 |
|
|
8,043 |
|
|
21,950 |
|
|
24,095 |
|
|||||
Equity-based compensation expense |
1,446 |
|
|
1,118 |
|
|
5,147 |
|
|
3,924 |
|
|||||
|
— |
|
|
— |
|
|
— |
|
|
87,016 |
|
|||||
Contingent consideration liability fair value adjustment |
— |
|
|
— |
|
|
(2,200 |
) |
|
— |
|
|||||
Restructuring-related charges including severance |
492 |
|
|
150 |
|
|
492 |
|
|
5,558 |
|
|||||
Legal reserve, settlements and recoveries |
— |
|
|
— |
|
|
— |
|
|
1,450 |
|
|||||
Equity investment loss |
— |
|
|
— |
|
|
— |
|
|
3,600 |
|
|||||
AMJP grant benefit |
(1,129 |
) |
|
— |
|
|
(1,129 |
) |
|
— |
|
|||||
Adjusted EBITDA |
$ |
2,836 |
|
|
$ |
(55 |
) |
|
$ |
2,703 |
|
|
$ |
25,865 |
|
|
|
|
|
|
|
|
|
|
|||||||||
Sales |
$ |
111,841 |
|
|
$ |
106,506 |
|
|
$ |
328,856 |
|
|
$ |
387,784 |
|
|
Adjusted EBITDA margin |
2.5 |
% |
|
(0.1 |
)% |
|
0.8 |
% |
|
6.7 |
% |
|||||
|
||||||||
CONSOLIDATED BALANCE SHEET DATA |
||||||||
($ in thousands) |
||||||||
|
(unaudited) |
|
|
|||||
|
|
|
|
|||||
ASSETS |
|
|
|
|||||
Cash and cash equivalents |
$ |
29,091 |
|
|
$ |
40,412 |
|
|
Accounts receivable and uncompleted contracts |
107,690 |
|
|
93,056 |
|
|||
Inventories |
157,163 |
|
|
157,059 |
|
|||
Other current assets |
34,135 |
|
|
26,420 |
|
|||
Assets held for sale |
3,760 |
|
|
— |
|
|||
Property, plant and equipment, net |
97,435 |
|
|
106,678 |
|
|||
Other long-term assets |
24,560 |
|
|
27,952 |
|
|||
Intangible assets, net |
98,190 |
|
|
109,886 |
|
|||
|
58,282 |
|
|
58,282 |
|
|||
Total assets |
$ |
610,306 |
|
|
$ |
619,745 |
|
|
|
|
|
|
|||||
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|||||
Accounts payable and accrued expenses |
$ |
79,567 |
|
|
$ |
69,165 |
|
|
Customer advances and deferred revenue |
22,249 |
|
|
24,571 |
|
|||
Long-term debt |
183,000 |
|
|
173,000 |
|
|||
Other liabilities |
73,830 |
|
|
82,638 |
|
|||
Shareholders' equity |
251,660 |
|
|
270,371 |
|
|||
Total liabilities and shareholders' equity |
$ |
610,306 |
|
|
$ |
619,745 |
|
|
|
||||||||||
CONSOLIDATED CASH FLOWS DATA |
||||||||||
(Unaudited, $ in thousands) |
||||||||||
|
|
|
|
|||||||
|
Nine Months Ended |
|||||||||
(Unaudited, $ in thousands) |
|
|
|
|||||||
Cash flows from operating activities: |
|
|
|
|||||||
Net loss |
$ |
(27,182 |
) |
|
|
$ |
(95,796 |
) |
|
|
Adjustments to reconcile net loss to cash from operating activities: |
|
|
|
|||||||
Depreciation and amortization |
21,950 |
|
|
|
24,095 |
|
|
|||
Provisions for non-cash losses on inventory and receivables |
2,750 |
|
|
|
4,535 |
|
|
|||
Equity-based compensation expense |
5,147 |
|
|
|
3,924 |
|
|
|||
Deferred tax (benefit) expense |
(145 |
) |
|
|
1,127 |
|
|
|||
Non-cash severance expense |
182 |
|
|
|
3,007 |
|
|
|||
Operating lease non-cash expense |
3,783 |
|
|
|
3,352 |
|
|
|||
Equity investment other than temporary impairment |
— |
|
|
|
3,493 |
|
|
|||
Impairment loss |
— |
|
|
|
87,016 |
|
|
|||
Contingent consideration liability fair value adjustment |
(2,200 |
) |
|
|
— |
|
|
|||
Other |
3,010 |
|
|
|
6,622 |
|
|
|||
Cash flows from changes in operating assets and liabilities: |
|
|
|
|||||||
Accounts receivable |
(15,027 |
) |
|
|
53,604 |
|
|
|||
Inventories |
(3,255 |
) |
|
|
(19,807 |
) |
|
|||
Accounts payable |
(1,883 |
) |
|
|
(9,589 |
) |
|
|||
Accrued expenses |
1,733 |
|
|
|
(11,340 |
) |
|
|||
Other current assets and liabilities |
(666 |
) |
|
|
(224 |
) |
|
|||
Customer advanced payments and deferred revenue |
(2,215 |
) |
|
|
(6,474 |
) |
|
|||
Income taxes |
217 |
|
|
|
(12,316 |
) |
|
|||
Operating lease liabilities |
(4,395 |
) |
|
|
(3,412 |
) |
|
|||
Supplemental retirement plan and other liabilities |
(304 |
) |
|
|
(304 |
) |
|
|||
Cash flows from operating activities |
(18,500 |
) |
|
|
31,513 |
|
|
|||
Cash flows from investing activities: |
|
|
|
|||||||
Capital expenditures |
(4,639 |
) |
|
|
(5,575 |
) |
|
|||
Proceeds on sale of assets |
30 |
|
|
|
1,600 |
|
|
|||
Cash flows from investing activities |
(4,609 |
) |
|
|
(3,975 |
) |
|
|||
Cash flows from financing activities: |
|
|
|
|||||||
Proceeds from long-term debt |
20,000 |
|
|
|
150,000 |
|
|
|||
Principal payments on long-term debt |
(10,000 |
) |
|
|
(170,000 |
) |
|
|||
Purchase of outstanding shares for treasury |
— |
|
|
|
(7,732 |
) |
|
|||
Financing fees |
— |
|
|
|
(360 |
) |
|
|||
Stock option activity |
3,187 |
|
|
|
33 |
|
|
|||
Finance lease principal payments |
(878 |
) |
|
|
(1,425 |
) |
|
|||
Cash flows from financing activities |
12,309 |
|
|
|
(29,484 |
) |
|
|||
Effect of exchange rates on cash |
(521 |
) |
|
|
(63 |
) |
|
|||
Decrease in cash and cash equivalents |
(11,321 |
) |
|
|
(2,009 |
) |
|
|||
Cash and cash equivalents at beginning of period |
40,412 |
|
|
|
31,906 |
|
|
|||
Cash and cash equivalents at end of period |
$ |
29,091 |
|
|
|
$ |
29,897 |
|
|
|
|
||||||||||||||||||||
SALES BY MARKET |
||||||||||||||||||||
(Unaudited, $ in thousands) |
||||||||||||||||||||
|
|
|
|
|
||||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
|
||||||||||||||||
|
|
|
% Change |
|
|
|
% Change |
% of Sales |
||||||||||||
Aerospace Segment |
|
|
|
|
|
|
|
|
||||||||||||
|
$ |
57,549 |
|
$ |
44,067 |
|
30.6 |
% |
|
$ |
143,550 |
|
$ |
214,390 |
|
(33.0 |
)% |
43.6 |
% |
|
Military |
17,064 |
|
18,164 |
|
(6.1 |
)% |
|
54,847 |
|
50,329 |
|
9.0 |
% |
16.7 |
% |
|||||
Business Jet |
12,109 |
|
14,711 |
|
(17.7 |
)% |
|
41,131 |
|
45,259 |
|
(9.1 |
)% |
12.5 |
% |
|||||
Other |
9,044 |
|
5,606 |
|
61.3 |
% |
|
26,874 |
|
16,213 |
|
65.8 |
% |
8.2 |
% |
|||||
Aerospace Total |
95,766 |
|
82,548 |
|
16.0 |
% |
|
266,402 |
|
326,191 |
|
(18.3 |
)% |
81.0 |
% |
|||||
|
|
|
|
|
|
|
|
|
||||||||||||
Test Systems Segment excluding Semiconductor |
16,075 |
|
23,373 |
|
(31.2 |
)% |
|
62,454 |
|
58,186 |
|
7.3 |
% |
19.0 |
% |
|||||
Total sales excluding Semiconductor |
111,841 |
|
105,921 |
|
5.6 |
% |
|
328,856 |
|
384,377 |
|
(14.4 |
)% |
100.0 |
% |
|||||
Test-Semiconductor |
— |
|
585 |
|
(100.0 |
)% |
|
— |
|
3,407 |
|
(100.0 |
)% |
— |
% |
|||||
|
|
|
|
|
|
|
|
|
||||||||||||
Total Sales |
$ |
111,841 |
|
$ |
106,506 |
|
5.0 |
% |
|
$ |
328,856 |
|
$ |
387,784 |
|
(15.2 |
)% |
|
||
SALES BY PRODUCT LINE |
||||||||||||||||||||
(Unaudited, $ in thousands) |
||||||||||||||||||||
|
|
|
|
|
||||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
|
||||||||||||||||
|
|
|
% Change |
|
|
|
% Change |
% of Sales |
||||||||||||
Aerospace Segment |
|
|
|
|
|
|
|
|
||||||||||||
|
$ |
38,650 |
|
$ |
32,481 |
|
19.0 |
% |
|
$ |
102,742 |
|
$ |
148,500 |
|
(30.8 |
)% |
31.2 |
% |
|
Lighting & Safety |
25,461 |
|
25,320 |
|
0.6 |
% |
|
76,929 |
|
90,973 |
|
(15.4 |
)% |
23.4 |
% |
|||||
Avionics |
14,491 |
|
16,104 |
|
(10.0 |
)% |
|
47,355 |
|
57,381 |
|
(17.5 |
)% |
14.4 |
% |
|||||
Systems Certification |
6,099 |
|
605 |
|
908.1 |
% |
|
7,937 |
|
5,596 |
|
41.8 |
% |
2.4 |
% |
|||||
Structures |
2,021 |
|
2,432 |
|
(16.9 |
)% |
|
4,565 |
|
7,528 |
|
(39.4 |
)% |
1.4 |
% |
|||||
Other |
9,044 |
|
5,606 |
|
61.3 |
% |
|
26,874 |
|
16,213 |
|
65.8 |
% |
8.2 |
% |
|||||
Aerospace Total |
95,766 |
|
82,548 |
|
16.0 |
% |
|
266,402 |
|
326,191 |
|
(18.3 |
)% |
81.0 |
% |
|||||
|
|
|
|
|
|
|
|
|
||||||||||||
Test Systems Segment excluding Semiconductor |
16,075 |
|
23,373 |
|
(31.2 |
)% |
|
62,454 |
|
58,186 |
|
7.3 |
% |
19.0 |
% |
|||||
Total sales excluding Semiconductor |
111,841 |
|
105,921 |
|
5.6 |
% |
|
328,856 |
|
384,377 |
|
(14.4 |
)% |
100.0 |
% |
|||||
Test-Semiconductor |
— |
|
585 |
|
(100.0 |
)% |
|
— |
|
3,407 |
|
(100.0 |
)% |
— |
% |
|||||
|
|
|
|
|
|
|
|
|
||||||||||||
Total Sales |
$ |
111,841 |
|
$ |
106,506 |
|
5.0 |
% |
|
$ |
328,856 |
|
$ |
387,784 |
|
(15.2 |
)% |
|
||
ORDER AND BACKLOG TREND (Unaudited, $ in thousands) |
||||||||||||||||
|
Q4 2020 |
Q1 2021 |
Q2 2021 |
Q3 2021 |
Trailing Twelve Months |
|||||||||||
|
|
|
|
|
|
|||||||||||
Sales |
|
|
|
|
|
|||||||||||
Aerospace |
$ |
91,797 |
|
$ |
81,416 |
|
$ |
89,220 |
|
$ |
95,766 |
|
$ |
358,199 |
|
|
Test Systems |
23,006 |
|
24,441 |
|
21,938 |
|
16,075 |
|
85,460 |
|
||||||
Total Sales |
$ |
114,803 |
|
$ |
105,857 |
|
$ |
111,158 |
|
$ |
111,841 |
|
$ |
443,659 |
|
|
|
|
|
|
|
|
|||||||||||
Bookings |
|
|
|
|
|
|||||||||||
Aerospace |
$ |
74,106 |
|
$ |
100,488 |
|
$ |
118,155 |
|
$ |
142,484 |
|
$ |
435,233 |
|
|
Test Systems |
41,877 |
|
19,497 |
|
8,166 |
|
11,052 |
|
80,592 |
|
||||||
Total Bookings |
$ |
115,983 |
|
$ |
119,985 |
|
$ |
126,321 |
|
$ |
153,536 |
|
$ |
515,825 |
|
|
|
|
|
|
|
|
|||||||||||
Backlog |
|
|
|
|
|
|||||||||||
Aerospace |
$ |
191,081 |
|
$ |
210,153 |
|
$ |
239,088 |
|
$ |
285,806 |
|
|
|||
Test Systems |
92,337 |
|
87,393 |
|
73,621 |
|
68,598 |
|
|
|||||||
Total Backlog |
$ |
283,418 |
|
$ |
297,546 |
|
$ |
312,709 |
|
$ |
354,404 |
|
N/A |
|||
|
|
|
|
|
|
|||||||||||
Book:Bill Ratio |
|
|
|
|
|
|||||||||||
Aerospace |
0.81 |
1.23 |
1.32 |
1.49 |
1.22 |
|||||||||||
Test Systems |
1.82 |
0.80 |
0.37 |
0.69 |
0.94 |
|||||||||||
Total Book:Bill |
1.01 |
1.13 |
1.14 |
1.37 |
1.16 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005376/en/
Company:
Phone: (716) 805-1599, ext. 159
Email: david.burney@astronics.com
Investor Relations:
Phone: (716) 843-3908
Email: dpawlowski@keiadvisors.com
Source:
FAQ
What are Astronics' Q3 2021 sales figures?
How did Astronics perform in terms of bookings in Q3 2021?
What was the net loss reported by Astronics in Q3 2021?
How has the supply chain affected Astronics' operations?